Corvus Pharmaceuticals Inc — キャッシュフロー (NASDAQ:CRVS)

Financials

営業活動によるキャッシュフロー -34.78 M-36.72 M-27.02 M-23.93 M-25.42 M-32.8 M -32.8 M 投資活動によるキャッシュフロー 44.77 M21.56 M-23.28 M15.54 M-27.48 M-7.8 M -7.8 M 財務活動によるキャッシュフロー 1.31 M62.16 M62.16 M7.86 M49.03 M36.43 M 36.43 M フリーキャッシュフロー -34.85 M-36.72 M-27.29 M-23.97 M-25.42 M-32.97 M -32.97 M

ニュース

Corvus Pharmaceuticals Stock: Strong Clinical Narrative, Already Priced For Success (CRVS)

Cantor Fitzgeraldが Corvus Pharmaceuticals の株式レーティングを再確認

Cantor Fitzgerald reiterates Corvus Pharmaceuticals stock rating

Oppenheimer raises Corvus Pharmaceuticals stock price target to $33

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticalsがアトピー性皮膚炎試験データで上昇

Corvus Pharmaceuticals rises on atopic dermatitis trial data

ポジティブな治験データ後にCorvus Pharmaceuticalsの決算発表が控える

Corvus Pharmaceuticals earnings on deck after positive trial data

Corvus決算発表控え、パイプライン期待は株価急騰を正当化できるか

Corvus earnings up next: Can pipeline buzz justify stock surge?

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27